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Melanosomal pH, Pink Locus Protein and their Roles in
Melanogenesis
To the editor:
We read with interest the article by Puri et al (2000) that reports
aberrant pH of melanosomes in pink-eyed dilution (p) mutant
mouse melanocytes. Although it is recognized that the product of
pink-eyed dilution locus (P protein) is important for melanogenesis
its speci®c function has not yet been identi®ed. In their paper Puri
et al propose that the P-protein is involved in acidi®cation of
melanosomal pH and that this acidic pH is essential for
melanogenesis. This proposal is based on the ®nding of a reduced
localization of the melanogenic enzyme TRP-1 in acidic
organelles. Whilst this could suggest that p-mutant mouse
melanocytes have fewer acidic melanosomes there are other
interpretations. For instance, it could be argued that in these
melanocytes there is a misrouting of TRP-1 protein.
It would indeed be a unique ®nding if, as Puri et al suggest, the
p-locus product is an ionic transporter involved in acidi®cation of
melanosomes. If this was the case then it is dif®cult to explain how
the P-protein, which does not utilize energy from ATP, could
function against a proton gradient of up to 1000-fold (pH 7.2 in
cytosol versus pH < 4 in melanosomes); however, this hypothesis
can be easily tested. If, as postulated by the authors, melanogenesis
only occurs in acidic melanosomes then it follows that neutraliz-
ation of intracellular acidic organelles should lead to a reduction of
melanogenesis in wild-type cells. The same change in p null mouse
melanocytes should result in little if any decrease in melanogenesis
as most melanosomes are already at a neutral pH. There are several
well-characterized substances available that neutralize intracellular
acidic organelles that could be used to test this hypothesis. These
include the selective vacuolar type proton pump inhibitors,
ba®lomycinA1 (BafA1) and concanomycinA (ConA), the H+/
Na + exchanger monensin, and ammonium chloride (NH4Cl).
Although Puri et al used monensin in their experiments to
demonstrate the speci®city of their method to visualize acidic
organelles, they made no mention of its effects on melanogenesis.
This was surprising since there are reports that treatment of mouse
melanoma cells with monensin or NH4Cl will cause immediate and
large increases in melanogenesis (Saeki and Oikawa, 1985; Fuller
et al, 1993). These ®ndings are consistent with the view that
mammalian tyrosinase has optimal conditions at neutral pH
(Hearing and Ekel, 1976; Townsend et al, 1984) but contrasts
with the hypothesis that acidic conditions favor melanogenesis
(Devi et al, 1987). In fact we also have observations that support the
view that melanin production is optimal at near neutral pH. We
have reported that the proton pump inhibitors, BafA1 and ConA,
induced melanogenesis in tyrosinase positive but amelanotic human
and mouse melanoma cells (Ancans and Thody, 2000) and our
observations have recently been con®rmed (Fuller et al, 2001).
Interestingly, one of the melanoma cell lines (FM3) used in our
study failed to express mRNA for the P-protein. Melanogenesis
was also restored in response to monensin and NH4Cl and in all
cultures this correlated with neutralization of acidic organelle pH.
We carried out similar experiments using the mouse melanocyte
line Melan-p1 (pcp/p25H) as well as wild-type P locus cell lines
Melan-a and Melan-b (kindly provided by Dr. D. Bennett).
Neutralization of acidic organelles resulted in a 4±5-fold increase in
the melanin content of Melan-p1 cells while there was no
signi®cant change with the Melan-a cells (wild type). Melan-b
cells that have wild-type P locus but reduced melanogenesis, as a
result of mutated b locus, responded with a slight increase in
melanin content (Fig 1). These results were not affected by the
protein synthesis inhibitor cycloheximide suggesting an activation
of pre-existing tyrosinase.
Our ®ndings are consistent with the idea that P protein has a role
in regulation of melanosomal pH but argue against the hypothesis
of acidi®cation. We would suggest the alternative hypothesis that
the P-locus protein has a role in the neutralization of melanosomal
pH and that this change facilitates tyrosinase activity. P-locus
protein is homologous to the E. coli Na+/H + antiporter and in
the light of our ®ndings it is reasonable to propose that the
P-protein functions as a channel that acts to reduce the proton
concentration inside the melanosome (as these organelles are related
to lysosomes). The observation made by Puri et al that both p null
melanocyte lines had a 25% increase in the total number of acidic
vesicles would be in keeping with this. Finally, our hypothesis does
not contradict the fact that melanosomes can be acidic; however,
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Figure 1. Effect of acidic intracellular organelle neutralization on
melanogenesis in mouse melanocytes with wild type p-locus
(Melan-a and b) and the pcp/p25H line Melan-p1. The cells were
treated with BafA1 (20 nM), monensin (10 mM), or NH4Cl (10 mM)
for 24 h and mean values of three experiments 6 SD are represented. *p
< 0.05; **p < 0.001.
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we would propose that stages of melanin formation that require
tyrosinase enzymatic activity will proceed optimally at near neutral
pH and that it is the p-locus product that functions to provide these
conditions. It is possible that the P-protein creates a neutral local
microenvironment and this is important in maintaining the high
molecular weight melanogenic complex of tyrosinase, TRP-1 and
-2. This would explain the absence of this complex in p-locus
mutated mouse cells (Lamoreux et al, 1995).
Janis Ancans, Martin J. Hoogduijn, Anthony J. Thody
Department of Biomedical Sciences, University of Bradford,
Bradford, U.K.
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A Novel a(± 4)-to-g Acceptor Splice Site Mutation Leads to
Three Bases Insertion in Ferrochelatase mRNA in a Patient
with Erythropoietic Protoporphyria
To the Editor:
Erythropoietic protoporphyria (EPP; MIM 177000) is an inherited
disorder caused by a partial de®ciency of ferrochelatase (FECH),
the last enzyme in the heme biosynthetic pathway (McKusick,
1998). In EPP patients, protoporphyrin accumulated in red blood
cells, skin, liver, and other organs causes photosensitivity and
occasionally life-threatening liver failure. Flushing, blister forma-
tion, pigmentation, and scarring of areas of skin exposed to sunlight
are the dermatologic symptoms of EPP (Todd, 1994). The level of
protoporphyrin in erythrocytes and feces is increased, but usually it
is not secreted in the urine. Human FECH cDNA contains
2443 bp. The FECH protein consists of 423 amino acids and has a
molecular weight of 40±42 kDa (Nakahashi et al, 1990). The
FECH gene spans at least 45 kb on the chromosome 18q21.3 and
contains 11 exons (Taketani et al, 1992). Over 38 mutations in the
FECH gene in EPP patients have been reported (Rufenacht et al,
1998). The characteristic FECH gene mutation in patients with
liver failure had been thought to be abnormal splicing leading to
exon skipping; however, it has been found that other mutations
resulting in a null allele are involved in EPP pedigrees with liver
complications (Rufenacht et al, 1998). Here we report a novel
mutation in the exon±intron boundary in a case of EPP in which
FECH activity in lymphocyte is 39.4% of normal.
A 23-y-old Japanese male who had photosensitivity visited our
University Clinic for a thorough examination. He had the ®rst
symptoms of painful erythematous swelling on his face, hands, and
feet at the age of 15 when he came home from a school trip. His
symptoms were getting worse. His parents were asymptomatic and
he had no siblings. There was no history of photosensitivity in
other family members. Routine blood test values and liver function
data were within normal limits. The minimal erythema doses of
ultraviolet (UV) A and UVB were normal. Examination of the
urine with a Wood light revealed no ¯uorescence. Blood
protoporphyrin was 1424 mg per dl (30±86), blood coproporphyrin
2 mg per dl (< 1), and urine coproporphyrin 30 mg per Gcreatinine
(47±151). Lymphocyte FECH activity in the patient measured by
the method (Li et al, 1987) was 24.4 nmol zinc-mesoporphyrin
formed per mg protein per h in contrast to 62.0 in a normal
control.
After informed consent, blood samples were collected from the
patient. Total RNA was extracted from the white blood cells by
the TRIZOL method (Life Technologies, Gibco BRL,
Gaithersburg, MD) and was subjected to oligo(dT) primed
cDNA synthesis using M-MuLV reverse transcriptase (RT)
(Amersham Pharmacia Biotech, Cleveland, OH). One microgram
of the ®rst strand cDNA was used as a template for PCR
ampli®cation with the primer pair, FCH-F; 5¢-
CGGGCCGAGGCTGCCCAGGC-3¢ and FCH-E5-B; 5¢-CTG-
TGGTGGAGCAGCTGTACTG-3¢ [cDNA nucleotide positions
±21~±2 and 567±588 (GenBank accession no. D00726), respect-
ively]. Ampli®cation conditions were 94°C for 3 min, followed
by 35 cycles of 94°C for 1 min, 62°C for 1 min, and 72°C for
2 min, and then ®nal extension at 72°C for 5 min. The PCR
product (619 bp) was cloned into pCR2.1-TOPO TA-cloning
vector (Invitrogen, Carlsbad, CA). Sequencing was carried out
using the Dye Terminators Cycle Sequencing Ready Reaction
(Perkin Elmer, Warrington, U.K.) on an ABI 310 genetic analyzer.
To con®rm the heterozygosity of the mutation, direct sequencing
was done with a smaller size of PCR product with primers, E4DF2;
5¢-AAGAGCAGTACCGCAGGATT-3¢ [cDNA nucleotide pos-
ition 359±378 (GenBank accession no. D00726)] and FCH-E5-B.
Genomic DNA was extracted from white blood cells with a
QIAamp Blood Kit (Qiagen, Hilden, Germany). Genomic DNA
from normal healthy Japanese people was used as controls. Speci®c
primers, FCint4up; 5¢-CTCTGAGGAATCTATATAAGG-3¢
(unpublished data) and FCex5dn; 5¢-GTGAAAGCAATAGCC-
CTTTC-3¢ [cDNA nucleotide position 547±566 (GenBank
accession no. D00726)] were designed for ampli®cation of the
intron 4±exon 5 boundary. Ampli®cation conditions were 95°C for
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